FEMASYS INC (FEMY): Form 8-K filed 2026-11-13
- Accepted by EDGAR
- 2026-11-13 16:47 ET
- Event date
- 2026-11-13
- Accession no.
- 0001140361-26-043791
- Original filing
- SEC EDGAR filing index
AI summary of the filing text. It can contain mistakes; the original filing is authoritative.
Femasys reports quarterly results and $30 million private placement
Femasys reported sales of $404,597 and a net loss of $4,564,815 for the quarter ended September 30, 2026. The company attributed the sales decline to the timing of international FemBloc orders. It also reported completing a $30 million private placement and receiving FDA approval of the modular premarket approval submission approach for FemBloc.
- Quarterly sales fell 44.5% to $404,597 from $729,394; U.S. sales increased to $347,039 from $336,594.
- Quarterly net loss was $4,564,815, compared to $4,194,821 for the quarter ended September 30, 2025.
- Completed a $30 million private placement to build out the U.S. commercial team and fund the FemBloc pivotal trial.
- Cash and cash equivalents were approximately $23.9 million as of September 30, 2026.
earningsfinancingregulatory
Items reported
- Item 2.02: Results of Operations and Financial Condition
The company publicly announced results of operations or financial condition for a completed period, most often a quarterly earnings release. The release itself is usually attached as Exhibit 99.1. Information under Item 2.02 is generally "furnished" rather than "filed". - Item 9.01: Financial Statements and Exhibits
Lists the financial statements, pro forma information and exhibits filed with the report. It almost always accompanies another Item and is rarely news on its own.
Documents
| Type | Description | Document |
|---|---|---|
| 8-K | 8-K | ef20085601_8k.htm |
| EX-99.1 | EXHIBIT 99.1 | ef20085601_ex99-1.htm |
The summary above was generated by AI from the filing text and checked automatically against it. Read the original documents on SEC EDGAR. How to read an 8-K.